Hubbry Logo
PsilocybePsilocybeMain
Open search
Psilocybe
Community hub
Psilocybe
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Psilocybe
Psilocybe
Psilocybe
View on Wikipedia
from Wikipedia

Psilocybe
Psilocybe semilanceata
Scientific classification Edit this classification
Kingdom: Fungi
Division: Basidiomycota
Class: Agaricomycetes
Order: Agaricales
Family: Hymenogastraceae
Genus: Psilocybe
(Fr.) P.Kumm. (1871)
Type species
Psilocybe semilanceata
(Fr.) P.Kumm. (1871)
Species

List of Psilocybe species

Synonyms[1]
  • Agaricus "trib." Psilocybe Fr. (1821)

Psilocybe (/ˌsaɪloʊˈsaɪbi/ SY-loh-SY-bee)[2] is a genus of gilled mushrooms, growing worldwide, in the family Hymenogastraceae. Many species contain the psychedelic compounds psilocybin and psilocin.

Taxonomy

[edit]

Taxonomic history

[edit]
P. tampanensis with spore prints

A 2002 study of the molecular phylogeny of the agarics[3] indicated the genus Psilocybe as then defined was polyphyletic, falling into two distinct clades that are not directly related to each other. The blue-staining hallucinogenic species constituted one clade and the non-bluing species the other. The previous type species of the genus, Psilocybe montana (now Deconica montana), was in the non-bluing clade, but in 2010, the type species was changed to P. semilanceata, a member of the bluing clade. A 2006 molecular phylogenetic study of the Agaricales by Matheny and colleagues, further demonstrated the separation of the bluing and non-bluing clades of Psilocybe in a larger, strongly supported phylogenetic tree of the Agaricales.[4]

Psilocybe had been placed taxonomically in the agaric family Strophariaceae based upon its spore and pileipellis morphology. The phylogenetic study by Matheny et al., placed the non-bluing Psilocybe and its close relatives in a basal position within the Strophariaceae, a sister taxon to a clade containing the other genera within that family. The bluing Psilocybe, however, form a clade that is sister to Galerina in the newly revised family, Hymenogastraceae which used to be restricted to secotioid, false-truffles.[4] The phylogenetic study by Moncalvo, et al. confirmed that the agaric genus Melanotus is simply a subgroup of the non-bluing Psilocybe, all of which are placed in Deconica, and also pointed to a close relationship between the latter genus and the genera Kuehneromyces and Phaeogalera.[3]

Modern classification

[edit]

In 2007, a paper by Redhead et al. proposed conserving the genus Psilocybe with Psilocybe semilanceata as its type species.[5] The suggestion was accepted by unanimous vote of the Nomenclature Committee for Fungi of the International Botanical Congress in 2010, meaning that P. semilanceata (a member of the bluing clade) now serves as the type species of the genus.[6] Since P. semilanceata is now the type species of the genus, the bluing hallucinogenic clade remained in the genus Psilocybe (Hymenogastraceae) while the non-bluing clade were transferred to the genus Deconica (Strophariaceae).[7] However, it has been demonstrated that P. fuscofulva, a species which used to be known as P. atrobrunnea, belongs to the genus Psilocybe s.s., but does not contain psychotropic compounds.[8] Negative results have also been published for P. fimetaria.[9]

Etymology

[edit]

The genus name Psilocybe is a compound of the Greek elements ψιλός (psilós) "bare" / "naked" and κύβη (kúbe) "head" / "swelling",[10] giving the meaning "bare-headed" (i.e. bald) referring to the mushroom's detachable pellicle (loose skin over the cap), which can resemble a bald pate.

Description

[edit]
P. ovoideocystidiata, Washington

Psilocybe fruit bodies are generally small, undistinguished mushrooms with a typical "little brown mushroom" morphology. Macroscopically, they are characterized by their small to occasionally medium size, brown to yellow-brown coloration, with a hygrophanous cap, and a spore print-color that ranges from lilac-brown to dark purple-brown (though rusty-brown colored varieties are known in at least one species).[11] Hallucinogenic species typically have a blue-staining reaction when the fruit body is bruised. Microscopically, they are characterized by pileipellis with hyphae that run parallel to the pileus surface, forming a cutis, by their lack of chrysocystidia, and by spores which are smooth, ellipsoid to rhomboid to subhexagonal in shape, with a distinct apical germ pore. Ecologically, all species of Psilocybe are saprotrophs, growing on various kinds of decaying organic matter.[12][13]

Distribution and habitat

[edit]
Global distribution of over 100 psychoactive species of genus Psilocybe mushrooms[14]: 207 
Approximate known range of Psilocybe cyanescens

Geographically, species in this genus are found throughout the world in most biomes.[15] The greatest species diversity seems to be in the neotropics, from Mesoamerica through Brazil and Chile.[14] Psilocybe are found in a variety of habitats and substrates. Many of the species found in temperate regions, such as Psilocybe cyanescens, seem to have an affinity for landscaped areas mulched with woodchips and are actually rather rare in natural settings removed from human habitation.[16] Contrary to popular belief, only a minority of Psilocybe species, such as P. cubensis and P. subcubensis, grow directly on feces.[17] Many other species are found in habitats such as mossy, grassy, or forest humus soils. Psilocybe arose about 65 million years ago.[18] In 2023, two new Psilocybe species (Hymenogastraceae), P. ingeli and P. maluti, were described from southern Africa.[19]

Psychoactivity

[edit]

Biochemistry and pharmacology

[edit]
Psilocybin molecule
Psilocin molecule

The psilocybin molecule is indirectly responsible for the hallucinogenic properties of the Psilocybe. This compound, as well as all other indole alkaloids, are derived from the amino acid tryptophan, being the only amino acid with the indole-amine ring. Tryptophan is converted to tryptamine by decarboxylation.[20] Two methylation steps occur producing DMT, another psychedelic compound.[20] Hydroxylation of this compound produces the more potent hallucinogen psilocin, followed by phosphorylation yielding psilocybin.[20] After ingestion of the psilocybin compound alkaline phosphatases present in the body's digestive system, kidneys, and possibly in the blood readily cleave the phosphoryl ester bond from psilocybin, yielding the hydroxyl compound, psilocin.[21] Psilocin is the chemical primarily responsible for the hallucinogenic effects of the Psilocybe.[21] The blue-staining species of Psilocybe are characterized by the presence of psilocin and psilocybin. This blue-staining reaction occurs after the fruit body has been injured, particularly near the base of the stalk.[22] This reaction is thought to be due to the oxidation of psilocybin after the outer surface of the fruit body has been breached.[23] The degree of bluing in a Psilocybe fruit body roughly correlates with the concentration of psilocin in the mushroom.[24] Psilocybin is chemically far more stable than psilocin, the latter compound being largely lost when the mushroom is heated or dried.[25]

The chemical structure of serotonin, a neurotransmitter, is similar to that of psilocin. The latter differs mainly by the location of one of the hydroxyls, and the addition of two methyl groups that make the molecule lipophilic (fat soluble), ergo capable of crossing the lipid membrane sheaths of the central nervous system.[26] After psilocybin has been ingested and dephosphorylated, to psilocin, the mechanism it uses in the brain has a direct agonist effect on the 5-HT serotonin receptors.[21] To explain this effect, the psilocin molecule essentially mimics the serotonin molecule, binding to the 5-HT receptors and initiating the same response as the serotonin. This effect explains the euphoria experienced by ingestion of this "agonist." Initially, hallucinogens were thought to blockade these serotonin neurotransmitters, but persistent research led to this agonist effect conclusion.[21]

Woolley and Campbell conducted research to determine whether the depletion of the hormone serotonin had a direct effect on mental disorders and that hallucinations might be due to an excess of serotonin.[27] Their results led them to study chemicals analogous to serotonin. They found that the psychoactive chemicals psilocybin and psilocin exhibited serotonin-like effects, however as dosage increased, these compounds acted as serotonin antagonists, psilocybin being comparable to the most potent antagonist yet discovered.[27] This is a plausible basis for the psychological effects of these hallucinogenic compounds.

Even though these chemicals are psychoactive and therefore the basidiomycete deemed toxic, there have been no reports of fatalities or induced internal organ damage directly associated with ingestion of these chemicals.[28] Misidentification of the fruit body could lead to ingestion of a lethal fungus.

Some psychoactive species contain baeocystin, norbaeocystin and β‐carboline monoamine oxidase inhibitors in addition to psilocin and psilocybin.[29]

Medical and psychiatric aspects

[edit]

The medicinal uses of the Psilocybe was recorded by Native Americans of Central America. Shamans, or curanderas would avidly ingest the "sacred mushrooms" for the extrasensory perceptual effects it gave them in order to better assess problems faced in their society.[30] The observed effects of the alkaloids found in these mushrooms has given rise to research into their possible uses for psychiatric medicine.[30] For details on contemporary research, see: Psilocybin: Medical research.

History and ethnography

[edit]
P. zapotecorum, Mexico
Main article: Psilocybin mushrooms

Hallucinogenic species of Psilocybe have a long history of use among the native peoples of Mesoamerica for religious communion, divination, and healing, from pre-Columbian times up to the present day. Hallucinogenic Psilocybe were known to the aboriginal Mexicans as teonanácatl (literally "divine mushroom")[31] and were reportedly served at the coronation of Moctezuma II in 1502. After the Spanish conquest of the Americas, the use of hallucinogenic plants and mushrooms, like other pre-Christian traditions, was forcibly suppressed and driven underground.[32]

By the 20th century, hallucinogenic mushroom use was thought by non-Native Americans to have disappeared entirely. However, in 1955, Valentina Wasson and R. Gordon Wasson became the first Westerners to actively participate in an indigenous mushroom ceremony. The Wassons did much to publicize their discovery, even publishing an article on their experiences in Life in 1957.[33] In 1956, Roger Heim identified the hallucinogenic mushroom that the Wassons had brought back from Mexico as Psilocybe and in 1958, Albert Hofmann first reported psilocin and psilocybin as the active compound in these mushrooms.[34] There is some skepticism as to whether or not these "sacred mushrooms" were actually in the genus Psilocybe. However, according to Heim's research in Mexico, he identified three species of Psilocybe that he believed were used in these native ceremonies. The species identified by Heim were; P. mexicana, P. caerulescens, and P. zapotecorum.[35][36][37] are a variety of Psilocybe mushrooms that make up the teonanácatl group of hallucinogenic mushrooms, including P. cubensis.[38] Isauro Nava Garcia, a Mazatec man, provided guidance to Heim while Heim conducted his field and culture work.[39] Garcia was an avid observer of the fungi in his environment while identifying specific characteristics about the fruit body of the Psilocybe his ancestors utilized, as well as knowing where they could be found.[39]

At present, hallucinogenic mushroom use has been reported among a number of groups spanning from central Mexico to Oaxaca, including groups of Nahua, Mixtecs, Mixe, Mazatecs, Zapotecs, and others.[40]

The popularization of entheogens by Wasson, Timothy Leary, and others has led to an explosion in the use of hallucinogenic Psilocybe throughout the world. By the early 1970s, a number of psychoactive Psilocybe species were described from temperate North America, Europe, and Asia and were widely collected. Books describing methods of cultivating P. cubensis in large quantities were also published. The relatively easy availability of hallucinogenic Psilocybe from wild and cultivated sources has made it among the most widely used of the hallucinogenic drugs.

[edit]
P. mexicana, Mexico
Main article: Legal status of psilocybin mushrooms

The purified chemicals psilocybin and psilocin are listed as Schedule II drugs under the United Nations 1971 Convention on Psychotropic Substances.[41] However, the UN drug treaties do not apply to cultivation, preparation, or international transport of psilocybin mushrooms.

Internationally, the two chemicals are generally considered controlled substances. However, there is much ambiguity about what is considered a "container" of these compounds. In several countries (e.g. Brazil), the chemicals themselves are listed as controlled substances, but the mushrooms that contain the chemicals are not, therefore deemed legal.[42] In the United States, possession of Psilocybe mushroom fruiting bodies is illegal in every state except for Florida. This is because the Supreme Court of Florida does not believe that these mushrooms could "reasonably be found to be containers of the schedule I substance, psilocybin".[43]

In the United States, there is no federal law mentioning the possession of Psilocybe spores. This is because only the psilocybin and psilocin compounds are considered Schedule I drugs and there is no presence of these compounds in the spores themselves, only in the fruiting body of the cultivated spores. However, there are several US states that have actually prohibited possession of these spores because they can be cultivated to produce these hallucinogenic, Schedule I drugs. These states includes California, Georgia,[44] and Idaho.[42][45]

However, possession of the spores by a qualified mycologist in California is legal if being put to use for research purposes, which must be approved by Research Advisory Panel.[46] If not authorized by law, possession of spores or cultivation of fruiting bodies of the Psilocybe is punishable to no more than one year in county jail or state prison.[46]

Psilocybin mushrooms, as well as other "soft drugs" which are stronger than cannabis but not synthetic, are legally available through smart shops in the Netherlands. Only the truffle form of magic mushrooms (such as P. tampanensis) are currently legal, but these still contain the active ingredients and produce similar effect as the caps and stalks.[47]

Notable species

[edit]
Main article: List of Psilocybe species
Psilocybe semilanceata

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Psilocybe

View on Grokipedia
from Grokipedia

Psilocybe is a of gilled mushrooms in the family , encompassing approximately 165 of primarily saprotrophic fungi that decompose such as wood, dung, or grassy soils. Many species exhibit a distinctive bluing reaction upon bruising, resulting from the oxidation of , a phosphorylated that the genus produces in varying concentrations. The psychoactive compounds and its dephosphorylated metabolite induce hallucinations, altered perception, and profound changes in when ingested, effects mediated by agonism at serotonin 5-HT2A receptors in the . The taxonomy of Psilocybe was comprehensively revised by Mexican mycologist in his 1983 , which cataloged known species including their distribution, chemistry, and history of use, with subsequent supplements addressing over 29 additional taxa and records post-1980. Species diversity is highest in the Neotropics, particularly , where over 50 hallucinogenic varieties have been documented, though the genus occurs globally in temperate and subtropical habitats. Phylogenetic analyses confirm that evolved independently in Psilocybe lineages, correlating with ecological adaptations to nutrient-rich substrates like dung. Psilocybe species have been employed in indigenous Mesoamerican rituals for to facilitate experiences, with modern scientific interest focusing on psilocybin's potential to alleviate and anxiety through neuroplasticity-enhancing mechanisms. Empirical studies demonstrate acute disruptions in connectivity, yielding transient ego dissolution and enduring reductions in negative affect, though risks include psychological distress in uncontrolled settings. Legal restrictions persist in many jurisdictions due to abuse potential, despite emerging evidence of therapeutic utility under clinical supervision.

Taxonomy and Classification

Taxonomic History

The genus Psilocybe was established by Swedish mycologist Elias Magnus Fries in 1838 as a within Agaricus, encompassing with conical to campanulate pilei, striate margins, and purplish-brown spore deposits, such as P. semilanceata (originally described as Agaricus semilanceatus in 1838). Paul Kummer elevated it to full generic rank in 1871, retaining Fries's P. montana (now synonymous with P. semilanceata), though early circumscriptions emphasized morphological traits like hygrophanous tissues and cartilaginous stipes without regard for biochemical properties. Through the late 19th and early 20th centuries, few additional species were added, with classifications remaining morphologically based and scattered across works like those of Narcisse Théophile Patouillard and others, often conflating Psilocybe with related genera in the Agaricales due to overlapping spore and lamella features. Interest surged in the 1950s following ethnobotanical expeditions by R. Gordon Wasson, which highlighted hallucinogenic uses among indigenous Mexican groups, prompting biochemical confirmation of psilocybin in species like P. mexicana by Albert Hofmann in 1958. Rolf Singer contributed significantly by transferring species such as Stropharia cubensis to Psilocybe cubensis in 1949, expanding the genus to include tropical, dung-inhabiting taxa based on bluing reactions and spore morphology. Mexican mycologist Gastón Guzmán advanced the from the 1970s onward, describing over 30 new species primarily from and revising the genus in his 1983 monograph, which recognized approximately 116 species divided into based on fruitbody form, cystidia types, and features. Guzmán's 1978 infrageneric classification into 16 , later refined by Singer in 1986 to emphasize bluing psychedelic species in subgenus Caerulescentes, underscored the genus's global diversity, with estimates reaching over 180 species by the through supplements accounting for post-1980 discoveries. These morphological frameworks persisted until molecular data in the 2000s revealed , leading to the 2007 proposal by Redhead et al. to conserve Psilocybe sensu stricto for psilocybin-producing, bluing species (type P. semilanceata), while reassigning non-psychedelic congeners to Deconica, a split ratified in 2010.

Modern Phylogeny and Species Delimitation

Modern phylogenetic analyses of Psilocybe have relied on molecular data, including nuclear ribosomal (ITS) regions, large subunit (LSU) rDNA, and multi-gene datasets, supplemented by recent phylogenomic approaches using of hundreds of loci from fungarium specimens. These methods have revealed that the Psilocybe sensu lato, as historically delimited by morphological traits like spore shape and cheilocystidia, is polyphyletic, with non-bluing species nested within or sister to genera such as Deconica and Stropharia in the family Hymenogastraceae. In contrast, the bluing, psilocybin-producing species form a monophyletic (Psilocybe sensu stricto), characterized by the evolution of psilocybin biosynthesis genes once in their lineage, as confirmed by . A landmark phylogenomic study in 2024 sequenced 71 specimens, including 23 type collections, to resolve relationships within the psychoactive , estimating the stem age of Psilocybe s.s. at approximately 67 million years ago (Cretaceous-Paleogene boundary) and crown diversification around 56 million years ago (early Eocene). This analysis employed maximum likelihood and on 1,341 orthologous genes, highlighting subclades corresponding to sections like Zapotecorum and Cyanescentes, and underscoring the role of wood-decomposition in driving diversification. Earlier multi-gene phylogenies, using markers like rpb1, rpb2, and ef-1α, similarly supported the of bluing Psilocybe while transferring over 50 non-bluing species to Deconica. These findings have refined sectional boundaries, with calibrations aligning diversification with global climatic shifts post-dinosaur extinction. Species delimitation in Psilocybe integrates phylogenetic evidence with morphological, ecological, and chemical traits, addressing cryptic diversity in complexes like P. cyanescens and P. cubensis. The ITS region serves as the primary DNA barcode for identification, but its resolution is limited in closely related taxa, necessitating multi-locus sequence typing or genome-wide markers to detect gene flow and delineate lineages. For instance, studies of the P. cyanescens complex in Europe used ITS, LSU, and rpb2 sequences alongside mating compatibility tests to identify distinct biological species, revealing hybridization barriers despite morphological overlap. Integrative approaches have described new species, such as P. ochraceocentrata in 2024 via ITS phylogenetics and microscopy, emphasizing the value of type sequencing to stabilize nomenclature amid ongoing discoveries of psychotropic taxa. Challenges persist in delimiting domesticated strains of P. cubensis, where genomic analyses detect admixture but confirm core monophyly within the psychoactive clade.

Etymology

The genus name Psilocybe is derived from the elements ψιλός (psilós), meaning "bare," "naked," or "smooth," and κύβη (kúbē or kúbe), meaning "head" or "swelling," collectively alluding to the smooth, bald, or naked appearance of the mushroom's pileus (). This etymological choice reflects early observations of the genus's characteristic glabrous or minimally scaly s, distinguishing them from more fibrillose or veiled counterparts in related taxa. The name was originally proposed by Swedish mycologist Elias Magnus Fries (Fr.) in the early 19th century as part of his classifications within the Agaricaceae, with formal sanctioning by German mycologist Paul Kummer in his 1871 work Führer in die Pilzkunde, elevating it to genus status under Psilocybe (Fr.) P. Kumm. Prior to this, species now assigned to Psilocybe were often placed in genera like Agaricus or Hypholoma, but the adoption of Psilocybe emphasized morphological traits such as the smooth cap texture over spore print color or gill attachment, which later proved pivotal in taxonomic revisions.

Morphology and Identification

Macroscopic Features

Psilocybe species are characterized by agaricoid fruiting bodies that are typically small to medium in size, with caps ranging from 0.5 to 10 cm in diameter depending on the species. The pileus is often conical, bell-shaped, or convex when young, expanding to plane or uplifted with age, and frequently features a persistent central umbo. Surface texture varies from smooth and viscid in wet conditions to silky or fibrillose when dry, with many species exhibiting hygrophanous properties that cause the cap to appear darker and more translucent when moist, often revealing radial striations. Coloration spans yellow-brown, , reddish-brown, to dark sepia or olivaceous tones, fading paler toward the margin. The lamellae are adnate to adnexed or nearly free, close to moderately spaced, and initially pallid to grayish before maturing to purplish-brown or blackish due to the deposition of dark purple-black spores. Edges are often concolorous or slightly paler, and serrulate in some species. A is absent in most, though rudimentary cortina-like remnants may occur in certain taxa like P. cyanescens. Stipes are central, terete, and range from filiform and slender (2-15 cm long, 1-3 mm thick) to more robust (up to 20 cm long, 5-15 mm thick), often equal or tapering upward with a bulbous base in some. The surface is typically silky-fibrillose, longitudinally striate, or pruinose at the apex, with colors matching the or paler, sometimes annulus-like zones from remnants. A distinctive bluing or greenish-blue reaction upon mechanical injury or aging is common across psilocybin-containing species, attributable to the oxidation of .

Microscopic Characteristics

The basidiospores of Psilocybe species are characteristically smooth, thick-walled, and to subrhomboid or sub in outline, typically measuring 5–12 μm in length by 3.5–8 μm in width across the genus, though dimensions vary by subgenus and . These spores feature a broad germ pore and often exhibit a plage, a darker region at the hilar appendix, contributing to their dark purple-brown to blackish-purple reaction in iodine stains and the genus's diagnostic dark purple-brown . Basidia are clavate to subcylindrical, predominantly 4-spored, and range from 15–35 μm in length by 5–10 μm in width, bearing sterigmata up to 3–5 μm long; clamp connections are commonly present at the bases and along generative hyphae. Pleurocystidia and cheilocystidia, when present, are typically lageniform, ventricose-rostrate, or , measuring 20–50 μm in length by 5–12 μm at the apex, often with crystalline encrustations or refractive contents in some , aiding subgeneric delimitation. The hymenophoral trama is regular to subregular, composed of cylindrical to inflated hyphae 3–15 μm wide, while the pileipellis varies from a cutis of interwoven hyphae to a trichodermium of erect elements, 50–200 μm thick. These microscopic traits, combined with molecular data, distinguish Psilocybe from congeners like Stropharia or Hypholoma, where spores lack the pronounced thick walls or germ pore prominence; however, interspecific variation necessitates species-specific examination for accurate identification.

Distinguishing from Lookalikes

Psilocybe species are most reliably distinguished from toxic lookalikes by a combination of macroscopic bruising response, spore print color, gill attachment, and habitat preferences. The characteristic bluing or blue-green discoloration of damaged flesh or gills, caused by oxidation of psilocybin-derived compounds, occurs in most Psilocybe taxa and is absent in deadly mimics such as Galerina species. Spore prints of Psilocybe yield a dark purple-brown to blackish deposit, contrasting with the rusty brown prints of Galerina marginata and the olivaceous to cinnamon-brown prints of Hypholoma fasciculare. The genus , containing responsible for , poses the greatest risk due to superficial similarities in cap shape and size, particularly with wood-inhabiting Psilocybe like P. cyanescens. fruits on decaying wood with a membranous annulus (ring) on the stem, often with decurrent gills, whereas Psilocybe typically lack a true annulus and have adnate to sinuate gills. Microscopically, spores feature a plage (a clear spot) and are smaller (8-12 µm), unlike the larger, angular Psilocybe spores without such features. Hypholoma species, such as H. fasciculare, cause gastrointestinal distress rather than organ failure but resemble Psilocybe in clustered growth on wood. They exhibit yellow-green edges when mature and lack bluing, with spore prints showing a greenish tint under . For species like P. semilanceata, non-toxic lookalikes include Panaeolus semiovatus, which has a fragile, evanescent but produces black prints without bluing; habitat specificity to well-grazed, nutrient-poor pastures further differentiates P. semilanceata. Tropical P. cubensis may be confused with Agrocybe pediades, a non-psychedelic saprobe on dung with similar convex caps but no bluing and a lighter brown ; Galerina risks persist in humid environments. Accurate identification requires fresh specimens for bruising tests and on white paper overnight, as dried material obscures these traits; consulting field guides or experts is essential, as no single feature is foolproof and misidentification has led to fatalities.

Ecology and Distribution

Habitat and Growth Conditions

Psilocybe species primarily occupy saprotrophic niches, decomposing lignocellulosic materials and nutrient-rich organic substrates in terrestrial ecosystems. They thrive in moist, temperate to subtropical environments, often emerging in humid conditions following , with many favoring well-drained soils enriched by decaying matter. Ancestral wood-decay associations predominate in certain clades, while independent transitions to soil-inhabiting and coprophilous lifestyles have occurred, reflecting adaptations to varied stages. Common substrates include animal dung, particularly from herbivores like cattle and horses, supporting coprophilous species such as , which colonizes dung pats in tropical and subtropical grasslands and pastures. Decaying hardwood chips and woody debris host lignicolous taxa like , often in mulch beds or forested edges where late-stage wood decay prevails. Grassland species, exemplified by , associate with grassy fields and meadows, potentially penetrating decaying grass roots in nutrient-poor, acidic soils. Other habitats encompass mossy areas, enriched soils near rivers, and disturbed sites with organic amendments like sugar cane mulch. Growth is favored by high levels exceeding 90% relative humidity in microhabitats, coupled with moderate temperatures ranging from 15–30°C depending on and season, though optimal conditions vary; for instance, P. cubensis proliferates in subtropical river valleys with consistent moisture. These fungi exhibit seasonal fruiting, often in autumn in temperate zones or year-round in , contingent on substrate availability and climatic cues like rainfall. Psilocybin production may confer selective advantages in competitive dung and wood-decay niches by deterring herbivores or altering microbial interactions, though direct empirical validation remains limited.

Global Distribution Patterns

The genus Psilocybe displays a , with species documented across all continents except , encompassing over 200 described taxa and estimates exceeding 300 based on recent phylogenetic analyses. This broad range reflects the genus's adaptability to diverse substrates, including dung, decaying wood, and grasslands, though species richness is unevenly distributed globally. Highest diversity concentrates in subtropical and tropical regions of the , particularly neotropical forests from southward through Central and . Mexico stands out as a major hotspot, harboring approximately 50 bluing (psilocybin-producing) Psilocybe species, many associated with cloud forests and traditional indigenous use. In contrast, temperate zones feature widespread but less diverse assemblages; for instance, , a saprotroph, occurs across , , , and parts of in cooler climates. Pantropical dung inhabitants like thrive in humid subtropical environments worldwide, often linked to cattle grazing areas, while wood-decay specialists such as are native to coastal habitats but have spread anthropogenically via wood chips to and other locales. Regional patterns reveal sparser representation in and , with isolated species in South African grasslands and East Asian woodlands, respectively, compared to denser clusters in the and . Human activities, including agriculture and , have facilitated the introduction of certain beyond native ranges, contributing to observed expansions in distribution. These patterns underscore a shaped by ecological niches and dispersal mechanisms, with ongoing surveys likely to refine understandings of and range limits.

Ecological Role and Interactions

Psilocybe species predominantly act as saprotrophic decomposers within fungal communities, breaking down lignocellulosic substrates such as decaying , leaf litter, herbaceous , and dung to facilitate recycling in terrestrial ecosystems. This process releases essential nutrients like carbon, , and back into the , supporting primary in forests, grasslands, and dung-enriched pastures where these fungi thrive. Unlike mycorrhizal or pathogenic fungi, Psilocybe exhibit no verified symbiotic or parasitic associations with or animals, confining their to free-living saprotrophy across wood-decay, soil-habitat, and coprophilous lifestyles. Phylogenetic analyses indicate that psilocybin likely evolved in ancestral wood-decomposing lineages within the , with subsequent radiations enabling to soil-inhabiting and dung-decomposing niches, enhancing their versatility in exploiting transient organic resources. In these roles, Psilocybe mycelia compete with other saprotrophs for substrates, potentially influencing microbial community dynamics through enzymatic degradation of complex polymers like and . The psychoactive compound , along with its oxidative byproducts, may confer a defensive ecological advantage by deterring grazing from and s that co-occur in decay habitats, as demonstrated by in arthropod bioassays and hypothesized formation upon fungal injury. Empirical support for this function remains preliminary, with ongoing research needed to quantify impacts on fungal fitness and broader trophic interactions in natural settings.

Biosynthesis and Chemistry

Primary Psychoactive Compounds


The primary psychoactive compounds in Psilocybe species are the indolealkylamine alkaloids psilocybin and psilocin. Psilocybin, systematically named 4-phosphoryloxy-N,N-dimethyltryptamine, constitutes the main stored form of the active agent in fungal tissues, typically comprising 0.2% to 1% of dry weight in potent species such as Psilocybe cubensis. Psilocin, or 4-hydroxy-N,N-dimethyltryptamine, occurs in lower concentrations but serves as the pharmacologically active metabolite, produced via dephosphorylation of psilocybin during metabolism. These compounds structurally resemble serotonin, enabling psilocin to bind primarily to 5-HT2A serotonin receptors, thereby inducing hallucinogenic effects. Minor tryptamines such as (4-phosphoryloxy-N-methyltryptamine) and (4-phosphoryloxytryptamine) are also present in trace amounts across many Psilocybe taxa, potentially modulating effects but lacking evidence as primary contributors to psychoactivity. , a quaternary ammonium analog, has been detected in select species like Psilocybe cubensis but its role remains understudied.

Biosynthetic Pathways

The biosynthesis of psilocybin in Psilocybe species begins with the amino acid L-tryptophan as the primary precursor, derived either directly from or indirectly via the . The process involves a compact biosynthetic (BGC) comprising four core enzyme-encoding genes—psiD, psiH, psiK, and psiM—that catalyze sequential modifications to yield , a phosphorylated derivative. This cluster is conserved across psilocybin-producing Psilocybe taxa, enabling efficient production during mycelial growth and fruiting body development. The initial step is of L-tryptophan to , mediated by PsiD, a specialized fungal L-tryptophan decarboxylase distinct from broader decarboxylases. PsiD exhibits high substrate specificity for L-tryptophan, with kinetic parameters including a Km of approximately 0.3 mM and a (kcat) of 1.2 s-1, ensuring directed flux into the pathway. Next, undergoes regioselective 4-hydroxylation at the ring by PsiH, a monooxygenase (or flavin-dependent analog in some characterizations), producing 4-hydroxytryptamine; this step requires molecular oxygen and NADPH, with PsiH showing preference for the para position to avoid steric hindrance. Phosphorylation follows, where PsiK, an ATP-dependent , transfers the γ-phosphate from ATP to the 4-hydroxy group of 4-hydroxytryptamine, forming 4-phosphoryloxytryptamine; this intermediate protects the phenol from oxidation and facilitates subsequent , with PsiK demonstrating a Km for 4-hydroxytryptamine around 0.1 mM. The final step involves PsiM, a dual-activity N-methyltransferase, which iteratively adds two methyl groups to the primary amine using S-adenosylmethionine (SAM) as the donor, yielding (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine). PsiM's sequential mono- and dimethylation produces pathway side products like (unphosphorylated monomethyl) and (monomethyl analog of psilocybin), whose ratios vary by species and environmental conditions. This pathway's enzymatic efficiency has been structurally elucidated in recent studies, revealing PsiK's accommodates the flexible scaffold via hydrogen bonding with the phosphate-binding loop, while PsiM's SAM-dependent mechanism involves transient formation for methylation. Expression of the BGC is upregulated during fruiting, correlating with accumulation up to 1-2% dry weight in species like P. cubensis. in non-Psilocybe genera highlights Psilocybe's canonical route as a model for fungal synthesis, though psiH variants may differ in cofactor dependency across lineages.

Variation Across Species

Psilocybin content in Psilocybe varies substantially, ranging from 0.01% to 2.40% of dry weight, reflecting genetic differences in biosynthetic expression and regulation across taxa. This variation extends to related tryptamines like , , and , with typically predominant and often exceeding levels by at least twofold in most . While the core biosynthetic pathway— involving enzymes such as PsiD (tryptophan decarboxylase), PsiK (), PsiH (hydroxylase), and PsiM (methyltransferase)—is conserved among psychedelic , quantitative output differs due to promoter strength, , and upstream precursor availability influenced by species-specific genomes. Specific examples illustrate this diversity: exhibits among the highest concentrations at 1.89% dry weight, whereas shows lower levels at 0.45%. In , a commonly analyzed species, fruiting bodies average approximately 0.99% (9.913 mg/g dry weight), with and other analogs present in trace amounts that vary by strain and substrate. , a phosphorylated analog, accumulates differentially; for instance, it constitutes up to 10-20% of total in some species like , potentially altering metabolic profiles compared to coprophilous species like P. cubensis where it is minimal. These interspecies differences in ratios—e.g., higher in certain Neotropical taxa—may influence rates , though empirical potency correlations remain understudied beyond total yield. Not all Psilocybe species produce significant tryptamines; saprobic or lignicolous taxa in non-psychedelic sections (e.g., Psilocybe coprophila) often yield negligible amounts, highlighting evolutionary divergence in the Psi gene cluster's functionality. Metabolomic analyses of multiple strains confirm broader chemical diversity, with 42 fungal isolates across nine species revealing unique profiles of minor indoles and β-carbolines alongside core psychedelics, underscoring that species boundaries correlate with distinct biosynthetic outputs rather than uniform composition. Environmental factors modulate these baselines intraspecifically, but drives the observed species-level disparities in compound abundance and diversity.

Pharmacological Effects

Mechanism of Action

Psilocybin, the principal psychoactive in Psilocybe species, serves as a that undergoes rapid enzymatic primarily in the liver and intestines to yield , the pharmacologically active compound responsible for hallucinogenic effects. structurally resembles serotonin and functions as a potent at serotonin receptors, with highest affinity for the 5-HT_{2A} subtype, where it exhibits binding stronger than serotonin itself. This agonism at 5-HT_{2A} receptors, located postsynaptically on cortical pyramidal neurons, is the primary molecular mechanism underlying the psychedelic properties of psilocybin-containing mushrooms. Receptor occupancy studies demonstrate dose-dependent 5-HT_{2A} engagement, reaching up to 72% at typical psychoactive doses, correlating directly with subjective psychedelic intensity. Psilocin also binds to other serotonin receptors, including 5-HT_{2C} and 5-HT_{1A}, though with lower affinity than at 5-HT_{2A}, and shows minimal interaction with or other monoamine receptors. The rank order of binding affinity is 5-HT_{2A} > 5-HT_{1A} > 5-HT_{2B}, supporting the central role of 5-HT_{2A} in mediating perceptual alterations, while ancillary receptor interactions may modulate anxiety or therapeutic outcomes. Upon binding, activates G-protein-coupled signaling pathways, including activation leading to production and intracellular calcium release, which disrupts integrity and promotes cortical desynchronization. This receptor-mediated signaling is antagonized by 5-HT_{2A}-selective blockers like , which abolish psychedelic effects, confirming specificity. Beyond primary , emerging evidence indicates may engage non-serotonergic targets, such as direct binding to TrkB receptors at concentrations relevant to , though these contribute secondarily to acute hallucinogenic action. Additionally, 5-HT_{1B} receptor activation has been implicated in modulating claustral signaling, potentially influencing sensory integration. However, the consensus from and pharmacological studies holds 5-HT_{2A} as the foundational mechanism, with downstream effects including enhanced glutamate release and reduced amygdala-prefrontal coupling driving experiential changes.

Acute Physiological and Psychological Effects

Ingestion of Psilocybe mushrooms, which contain that is rapidly dephosphorylated to the active metabolite , elicits dose-dependent acute physiological effects typically onsetting within 20-40 minutes and peaking at 60-90 minutes post-ingestion. Common effects include transient elevations in systolic and diastolic , , and body temperature, alongside (pupil dilation). In controlled studies with therapeutic doses (10-30 mg ), elevated occurred in up to 76% of participants, resolving within 24 hours. affects 4-48% of users, often resolving within 60 minutes, while and are reported with relative risks of 1.99 and 5.81 versus , respectively, and typically subside within 48 hours. Hormonal perturbations, such as increases in , , ACTH, and TSH, have been observed at higher doses (e.g., 315 µg/kg), but no significant changes in electrocardiogram readings or core body temperature were noted in double-blind trials. Acute psychological effects manifest as profound alterations in consciousness, including perceptual distortions, visual and auditory hallucinations, synesthesia, and a distorted sense of time. Users often experience intensified emotions ranging from euphoria and bliss to anxiety and terror, with dose-dependent reductions in cognitive performance, such as impaired executive function and attention, persisting during intoxication. Ego dissolution—a temporary loss of self-boundaries—and oceanic boundlessness are frequently reported, contributing to mystical-type experiences rated as highly meaningful. In healthy volunteers, high doses (e.g., 215-315 µg/kg) induce significant changes in affect, cognition, and self-perception, including increased dreaminess and emotional excitability, though transient anxiety occurs in a minority (e.g., 4-26% incidence). These effects generally resolve within 6-8 hours, with no evidence of persistent psychological impairment in controlled settings.

Potential Long-Term Neurological Impacts

, the primary psychoactive compound in Psilocybe species, has been associated with potential long-term enhancements in neural plasticity, primarily observed in preclinical and limited human studies involving therapeutic dosing. In frontal cortex pyramidal neurons of mice, a single dose induced rapid growth persisting up to a month, suggesting structural remodeling that could underlie sustained behavioral changes. Human neuroimaging reveals persistent desynchronization of brain networks, including reduced functional connectivity between the anterior hippocampus and lasting weeks post-administration, potentially contributing to decreased rumination in depression. These alterations align with increased expression of plasticity-related proteins like BDNF, though human evidence remains correlational and derived from short follow-up periods rather than decades-long exposure. Conversely, rare adverse outcomes include (HPPD), characterized by ongoing visual distortions such as trails, halos, or geometric patterns reminiscent of acute effects, reported in case studies following consumption. HPPD prevalence is low and difficult to quantify, with symptoms potentially resolving slowly over years or persisting indefinitely, often linked to higher doses or predisposing factors like anxiety; one review estimates it affects a subset of users but lacks large-scale epidemiological data specific to . Flashback-like phenomena occur in up to 9.2% of healthy subjects post-, though these are typically transient and not necessarily indicative of permanent neurological damage. Data on chronic recreational use of Psilocybe mushrooms, involving repeated exposures over years, is sparse and confounded by polydrug factors. Lifetime psychedelic users exhibit differences in cortical thickness and thalamic volume compared to non-users, potentially reflecting adaptive plasticity or subtle , but and specificity remain unestablished. Systematic reviews highlight enduring psychological shifts like reduced anxiety and increased , yet caution that long-term neurological risks, including potential for persistent in vulnerable individuals, require prospective cohort studies beyond current therapeutic trials focused on single doses. Overall, while neuroplasticity-promoting effects predominate in controlled contexts, uncontrolled long-term impacts warrant toward unsubstantiated claims of universal benefit absent rigorous, unbiased longitudinal evidence.

Therapeutic Research and Claims

Historical and Early Studies

Psilocybin's entry into Western therapeutic research followed its isolation from by at Sandoz Laboratories in 1958, with the compound synthesized for clinical distribution as Indocybin starting in 1959. Early investigations, modeled on contemporaneous studies, emphasized its role in augmenting by inducing profound purported to enhance self-insight and emotional processing. Researchers like , who coined the term "psychedelic" in 1957, extended exploratory work to psilocybin for conditions including alcoholism, viewing high-dose sessions as catalysts for transformative experiences that could interrupt addictive patterns. Small cohorts reported subjective improvements, such as increased motivation for abstinence, but outcomes relied heavily on anecdotal reports and therapist interpretations rather than objective metrics. In the early 1960s, trials targeted psychiatric disorders like and anxiety, often administering doses of 10-30 mg in controlled settings. For , results were inconsistent; some patients exhibited transient symptom reduction, but others experienced acute exacerbations mimicking psychotic episodes, leading to cautions against use in this population. Osmond and , building on their experiments with (which yielded 40-45% one-year abstinence in ), applied similar paradigms to psilocybin, hypothesizing biochemical similarities could yield comparable insights into dependency cycles. However, psilocybin-specific alcoholism studies remained limited and uncontrolled, with claims undermined by and absence of blinding. By the mid-1960s, over 40 psilocybin-assisted studies had enrolled thousands of participants worldwide, primarily for neuroses, personality disorders, and anxiety, where preliminary data suggested potential for rapid symptom relief through mystical-type experiences. Yet, methodological shortcomings—small samples (often n<20), lack of randomization, and confounding by expectancy effects—precluded definitive conclusions, while rising recreational misuse fueled skepticism. Research curtailed sharply after psilocybin's Schedule I classification in the U.S. Controlled Substances Act of 1970, reflecting regulatory prioritization of abuse potential over therapeutic signals.

Recent Clinical Trials and Evidence

In 2023 and 2024, multiple phase 2 and early phase 3 trials continued to investigate synthetic formulations, primarily for treatment-resistant depression (TRD), with COMPASS Pathways' COMP360 receiving FDA Breakthrough Therapy Designation in prior years to expedite development. A December 2024 randomized controlled trial published in JAMA Network Open examined single-dose therapy (25 mg) with psychotherapy support in 24 clinicians experiencing depressive symptoms, reporting significant reductions in depression scores on the GRID-HAMD scale at 1-week and 4-week follow-ups compared to waitlist controls, with 50% of participants achieving remission by week 4 and sustained benefits observed in open-label extensions up to 12 months. Effect sizes were large (Cohen's d > 1.0), though the sample was small and limited to a specific professional population, with no serious adverse events beyond transient anxiety during sessions. The most advanced recent evidence emerged from Pathways' pivotal phase 3 (COMP005), reported on June 23, 2025, which enrolled 261 adults with TRD across 22 sites in a double-blind, -controlled design testing a single 25 mg dose of COMP360 with psychological support. The primary endpoint of change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 3 was met, with participants receiving active treatment showing a statistically significant greater reduction versus ( difference of -4.7 points, p < 0.001), and sustained benefits at week 6 ( difference -3.6 points). No treatment-related serious adverse events occurred, with headaches and as common mild side effects resolving within days. Response rates (≥50% MADRS reduction) reached approximately 30% in the psilocybin arm at week 3, compared to 10% for , though durability beyond 12 weeks requires further data from ongoing extensions. Ongoing trials as of October 2025 include UCSF and UCSD studies targeting for TRD, in , and comorbid conditions like depression, with enrollment focusing on 18-75-year-olds and incorporating to assess neural mechanisms. Smaller 2025 pilot studies, such as a trial with seven TRD participants, reported rapid symptom relief post-25 mg (MADRS reductions of 15-20 points at 1 week), but lacked controls and emphasized the need for larger validations. Evidence for other indications remains preliminary: a 2024 phase 2 trial analog (CYB003, a deuterated derivative) showed 75% remission in major depression at 4 months, earning FDA Breakthrough Designation, but full data for anxiety, , or PTSD in recent years derive from open-label or small RCTs with mixed durability. continues phase 2 extensions for , reporting 80% abstinence rates at 12 months in prior cohorts, though 2023-2025 updates confirm no new large-scale RCTs completed. Overall, while phase 3 data affirm acute effects, long-term efficacy and optimal dosing protocols await confirmatory trials.

Criticisms of Research Methodology and Hype

Criticisms of psychedelic research, including studies on derived from Psilocybe species, center on persistent methodological shortcomings that undermine the reliability of findings. A of 10 randomized clinical trials (RCTs) on psychedelic-assisted found that 9 exhibited a high overall of , primarily due to inadequate blinding of participants and personnel. Blinding failures are exacerbated by the drugs' intense subjective effects, such as hallucinations and altered , which participants readily distinguish from placebos; for instance, in one trial for anxiety, 100% of participants correctly guessed their assignment, while in another for depression, 94% did so. , intended to prevent , was rarely reported and often unsuccessful, further compromising trial integrity. Expectancy effects represent a core confound, as participants' prior beliefs about psychedelics' benefits inflate perceived independent of pharmacological action. In psychedelic RCTs, de-blinding enables high response expectancies, potentially overestimating treatment effects by , though the precise magnitude remains unquantified in most studies. Guidelines for improving psychedelic science highlight that such effects threaten , recommending assessments of masking and the use of psychedelic-naïve participants to mitigate them. Small, non-representative samples—often (Western, educated, industrialized, rich, democratic) volunteers—limit generalizability, while per-protocol analyses exclude real-world deviations, artificially enhancing apparent safety and . Reporting practices amplify these issues through selective emphasis on positive outcomes and underreporting of harms. Publication bias favors significant results, with preregistration and protocol adherence lacking in many trials, enabling post-hoc outcome switching—such as reclassifying secondary endpoints as primary to highlight benefits. data gaps persist, including incomplete long-term tracking of adverse events like ontological shock or suicidality; one trial for reported elevated in active doses versus . Hype surrounding psilocybin's therapeutic potential, particularly for depression, often outpaces evidence, driven by enthusiastic media portrayals and commercial interests. Preliminary Phase II results are extrapolated to broad claims of "" efficacy, despite methodological flaws and the controlled settings of trials, which do not reflect unsupervised real-world use where risks like exacerbation in vulnerable individuals (e.g., those with bipolar traits) are heightened. Critics argue this mirrors mid-20th-century overoptimism, potentially rushing approvals without addressing blinding confounds or diverse population needs, as commercial pressures prioritize market entry over rigorous validation. Such narratives risk public misconception, as trials like those comparing psilocybin to show no significant superiority when biases are considered, underscoring the need for skepticism toward unverified transformative claims.

Risks and Adverse Effects

Acute Toxicity and Overdose Potential

Psilocybin, the primary psychoactive compound in Psilocybe mushrooms, demonstrates low acute physiological toxicity in both animal models and human case reports, with no verified fatalities attributed solely to overdose of the pure substance. Animal studies indicate an LD50 (lethal dose for 50% of subjects) exceeding 280 mg/kg intravenously in rabbits and higher oral thresholds in rodents, far surpassing typical human psychoactive doses of 10-30 mg. In humans, achieving a lethal plasma concentration would require ingestion of quantities equivalent to thousands of dried Psilocybe caps, which is physiologically implausible due to dose-limiting factors such as nausea, vomiting, and early-onset psychological effects that deter further consumption. Overdose potential remains minimal, as emesis typically occurs before absorption of toxic levels, rendering lethal intoxication from Psilocybe alone exceedingly rare across documented exposures. Systematic reviews of data and control reports confirm that while acute adverse events like , , and gastrointestinal distress occur, they are self-limiting and resolve within 24-48 hours without intervention in most cases. No direct causal links to death from overdose have been established in peer-reviewed literature; rare fatalities involving Psilocybe consumption often involve confounding factors such as , accidents during impaired states, or misidentification with toxic species like those containing . The primary acute risks manifest psychologically rather than toxically, including transient anxiety, , or perceptual distortions that, while distressing, do not escalate to life-threatening physiological compromise in isolation. Therapeutic trials administering controlled doses up to 30 mg report tolerable profiles, with adverse effects like elevated peaking early and subsiding rapidly, underscoring the compound's narrow margin for physical harm relative to its psychoactive potency. This low overdose threshold aligns with broader pharmacological assessments classifying among substances with high safety indices, though individual variability in set, setting, and co-ingestants can amplify non-toxic hazards.

Psychological and Behavioral Risks

Consumption of Psilocybe mushrooms, which contain , can induce acute psychological distress including intense fear, panic attacks, and paranoia during the hallucinogenic experience, often termed a "." These episodes arise from distorted perceptions, , and ego dissolution, potentially leading to severe anxiety or terror in uncontrolled settings. Individuals with predisposing factors, such as a personal or family history of psychiatric disorders, face heightened vulnerability to such reactions. Behavioral impairments during intoxication include reduced awareness of surroundings, impaired , and loss of time sense, increasing risks of accidents or hazardous actions like wandering into . Users may engage in impulsive or self-endangering behaviors due to altered judgment, with reports of agitation prompting emergency interventions. In rare cases, acute manifests, characterized by delusions or hallucinations persisting beyond the drug's effects, particularly in those with latent vulnerabilities like depression or personality disorders. Case studies document prolonged , , and catatonia following psilocybin ingestion, resolving only after treatment. Long-term psychological risks encompass (HPPD), involving recurrent visual disturbances such as trails, halos, or geometric patterns lasting months to years post-use. Symptoms can persist for over five years, causing significant distress and functional impairment. Repeated exposure, as in therapeutic retreats, has led to enduring anxiety, concentration deficits, and in case reports. Among bipolar individuals, use correlates with exacerbated manic symptoms and disturbances in approximately one-third of surveyed cases. While is negligible, psychological of risky patterns may occur in susceptible users, though population-level data indicate low overall incidence of chronic behavioral changes.

Long-Term Health Concerns and Case Evidence

While epidemiological data indicate that severe long-term adverse effects from psilocybin are uncommon, with estimated incidences of persistent as low as 1 in 50,000 users in historical surveys, case reports highlight risks of enduring psychiatric disturbances, particularly among predisposed individuals with personal or family histories of mental illness. These include (HPPD), characterized by recurrent visual phenomena such as trails, halos, or geometric patterns persisting months to years post-use, and persistent psychotic episodes featuring delusions, hallucinations, or catatonia. Documented cases of psilocybin-induced persistent psychosis often involve repeated or high-dose exposure in vulnerable users. In one report, a male patient with prior depression developed sustained psychotic symptoms, including auditory hallucinations and catatonic features, lasting several months after intermittent psilocybin use over prior months, requiring treatment for resolution. Another involved a undergoing training who consumed high doses of psilocybin-containing mushrooms repeatedly over six months, resulting in profound worsening of anxiety, depression, and symptoms that persisted beyond cessation, linked to cumulative serotonergic effects. A case series further described varied presentations, including , , and persisting weeks to months, with some requiring hospitalization; these outcomes were more frequent in users with subclinical vulnerabilities, underscoring causal links via overstimulation exacerbating latent dysregulation. HPPD cases tied to psilocybin typically feature milder Type I symptoms (e.g., flash-like visuals) but can progress to debilitating Type II forms with anxiety-aggravated distortions. A reported instance involved an 18-year-old male experiencing ongoing perceptual anomalies, including afterimages and color intensification, following combined and intoxication, with symptoms enduring over a year despite . In a broader series, accounted for three of multiple HPPD attributions among users, often co-occurring with other psychedelics or polydrug use, suggesting potentiation by repeated exposure or individual factors. Qualitative analyses of long-term negative responses also identified rare escalations to new-onset or PTSD with psychotic features in interviewed users, with symptoms traceable to a single intense episode years prior. Cognitive long-term impacts appear minimal based on systematic reviews, with no consistent evidence of deficits in , executive function, or ; acute impairments resolve, and some studies note persistent desynchronization in connectivity potentially underlying reported insights without functional decline. Physical concerns, such as cardiovascular risks from chronic 5-HT2B agonism leading to valvular , remain theoretical for , with animal models showing no remodeling from analogous low-dose psychedelics, though human warrants monitoring given structural similarities to implicated agents. Overall, these rare but verifiable cases emphasize predispositional screening to mitigate harms, as empirical causality is supported by temporal proximity and exclusion of confounders in controlled reports.

Historical and Cultural Context

Pre-Modern and Indigenous Uses

Psilocybe mushrooms have been utilized in ritual and therapeutic contexts by indigenous Mesoamerican peoples for millennia, with the earliest archaeological indications including mushroom-shaped stone artifacts from sites in , , , and El Salvador dating to approximately 1000 BCE. These "mushroom stones" are interpreted by scholars as representations of psychoactive fungi employed in religious ceremonies, though direct chemical residue analysis confirming psilocybin presence remains absent. Historical accounts from 16th-century Spanish chroniclers, such as , document Aztec use of Psilocybe species, referred to in as teonanácatl ("flesh of the gods"), for , healing, and communal rites prior to European contact. Among contemporary indigenous groups preserving these traditions, the people of , , ingest Psilocybe species like P. mexicana and P. caerulescens during veladas—nocturnal healing ceremonies led by shamans (chuchauras)—to diagnose illnesses, commune with spirits, and facilitate cures through visions. Known locally as ndi xijtho ("little ones that sprout"), these mushrooms are prepared as teas or consumed fresh, with usage tied to seasonal availability following rains. Similar practices occur among Zapotec and communities in the region, where Psilocybe fungi serve entheogenic roles in shamanic healing and prophecy, distinct from recreational consumption. Evidence for widespread pre-modern use beyond is sparse and largely speculative, with no verified archaeological or ethnohistorical records of ritual Psilocybe ingestion in ancient , , or other continents despite the genus's global distribution. Post-conquest suppression by colonial authorities targeted these practices, associating them with , yet they persisted clandestinely among indigenous groups.

20th-Century Discovery and Popularization

In 1955, banker and amateur mycologist R. Gordon Wasson, accompanied by photographer Allan Richardson, traveled to the Sierra Mazateca region of Oaxaca, Mexico, where they participated in a traditional Mazatec healing ceremony led by shaman María Sabina, consuming psychoactive mushrooms identified later as species of Psilocybe. Wasson's account of the experience, detailing vivid hallucinations and spiritual insights, was published as "Seeking the Magic Mushroom" in the May 13, 1957, issue of Life magazine, marking the first widespread public exposure of these mushrooms' effects in Western culture and sparking global interest among scientists, ethnobotanists, and the public. French mycologist Roger Heim, who accompanied Wasson on a subsequent 1956 expedition, taxonomically classified the ingested fungi as and , sending dried specimens to Swiss chemist at Sandoz Laboratories. In March 1958, Hofmann isolated the active compounds and from these samples, confirming their chemical structures and synthesizing in pure form by 1959; Sandoz subsequently marketed it as Indocybin for psychiatric research. This breakthrough enabled controlled studies, distinguishing the mushrooms' from and facilitating early therapeutic trials in and the . The 1960s saw rapid popularization through academic and countercultural channels, particularly via Harvard University's Psilocybin Project, initiated in 1960 by psychologist after obtaining Indocybin from . Leary, collaborating with Richard Alpert, conducted experiments on over 200 participants, including prison inmates and divinity students, reporting profound personality changes and mystical experiences that Leary advocated as tools for consciousness expansion in publications like (1964). The project's ethical controversies, including unauthorized dosing and Leary's public proselytizing, led to its termination and the dismissals of Leary and Alpert in 1963, yet it fueled the psychedelic movement's growth amid the era's social upheavals. By the late , cultivation techniques disseminated via underground networks like the further democratized access, though this preceded escalating legal restrictions.

Contemporary Recreational and Subcultural Use

In the United States, past-year use among adults rose to approximately 3%—equating to about 8 million individuals—in 2023, marking as the most commonly used psychedelic substance. Lifetime prevalence increased from 10% in 2019 (roughly 25 million adults) to 12.1% by 2023 (over 31 million), with sharper upticks among those aged 30 and older (188% increase) and 18- to 29-year-olds (44% increase) since 2019. This surge correlates with heightened seizures, from 402 incidents in 2017 to 1,396 in 2022, alongside increased total weight of confiscated material. Users often report recreational motivations including altered perception, introspection, and self-perceived benefits, though such self-reports derive from naturalistic surveys rather than controlled settings. Microdosing—consuming sub-perceptual doses of , typically 0.1-0.3 grams of dried mushrooms every few days—has gained traction as a recreational practice for purported enhancements in mood, , and focus. In a 2024 global survey of over 6,000 psychedelic consumers, was the predominant microdosing substance (74.5% of respondents), with 52.5% dosing multiple times monthly, often alongside or . Nearly half of recent U.S. users opted for in the past year, a pattern observed across demographics but particularly among self-experimenters seeking cognitive or emotional optimization without full hallucinogenic effects. Subcultural use centers on psychonaut communities, where enthusiasts—often well-educated, tech-oriented individuals—systematically explore for expansion, with users exhibiting distinct neural patterns linked to informed dosing practices. Recreational consumption frequently occurs at music festivals, where psychedelics like amplify sensory and social experiences, though such settings introduce variables like polydrug use and variable preparation quality. These contexts emphasize through preparation and integration, contrasting with casual use, and align with broader psychedelic subcultures valuing ecological awareness and over institutional frameworks. and cultivation of like Psilocybe cubensis sustain these groups, fueled by online knowledge-sharing despite legal risks.

International Scheduling and Prohibitions

and , the principal psychoactive alkaloids in Psilocybe species, are controlled as Schedule I substances under the , adopted on 21 February 1971 in and entering into force on 16 August 1976. Schedule I encompasses substances deemed to present the highest degree of risk to , with minimal acknowledged therapeutic value and substantial potential for abuse, as determined by the World Health Organization's recommendations during the convention's formulation. The treaty lists these compounds explicitly as "Psilocybine" (O-phosphoryl-psilocine, with chemical description 3-[2-(dimethylamino)ethyl]indol-4-yl dihydrogen phosphate) and "Psilocine" (also psilotsin, 3-[2-(dimethylamino)ethyl]indol-4-ol). Under Articles 3 and 7 of the convention, ratifying states must enact domestic laws prohibiting the production, extraction, manufacture, export, import, distribution, trade, and possession of Schedule I psychotropics for non-medical or non-scientific purposes, with strict licensing required for any authorized activities. This framework effectively bans the harvesting, cultivation, and possession of Psilocybe mushrooms in most jurisdictions, as their growth constitutes the manufacture of controlled substances. The treaty has been ratified by 183 states as of 2013, encompassing the vast majority of member states and imposing binding obligations absent reservations specifically exempting these substances. The convention does not directly classify Psilocybe fungal species, sclerotia, or spores, which lack psilocybin or until and maturation; however, international obligations typically extend to prohibiting cultivation intent on producing scheduled substances, with spores often regulated nationally to circumvent this gap. No amendments or rescheduling efforts have altered this status for psilocybin or , despite emerging research on potential therapeutic applications, maintaining the prohibitions as originally established.

National Variations and Exceptions

In , psilocybin was approved for medical use on July 1, 2023, marking the first national authorization for psychiatrists to prescribe it under the Therapeutic Goods Administration's Special Access Scheme for conditions like , though recreational possession remains prohibited. In , psilocybin is classified as a Schedule III substance under the , but exemptions are granted via Health Canada's for therapeutic administration in cases of or clinical trials, with over 100 such approvals issued by 2022. The bans the cultivation, sale, and possession of Psilocybe mushrooms since a 2008 amendment to the Opium Act, yet permits the trade and consumption of magic truffles—sclerotia containing —as they are not explicitly classified as mushrooms, enabling regulated sales in licensed smart shops. Portugal's 2001 National Strategy for the Fight Against Drugs decriminalized personal possession of up to 0.5 grams of psilocybin mushrooms, redirecting users to dissuasion commissions for administrative sanctions rather than criminal penalties, a credited with reducing transmission among injectors by 95% from 2001 to 2019. Jamaica has never enacted prohibitions on psilocybin mushrooms, allowing legal cultivation, possession, and retreats since independence in 1962, with no listing for or . In Brazil, unprocessed Psilocybe mushrooms are unregulated under , permitting possession and use, though extraction or synthesis of is criminalized as drug production. The Bahamas and permit personal possession and consumption without penalties, but prohibit commercial sale or distribution. Exceptions for research persist in nations like , where clinical trials for in depression treatment received approval from the Danish Medicines Agency in 2017, and the , which decriminalized possession of small amounts (up to 1.5 grams dried) since 2010 amendments to drug laws. In contrast, strict prohibitions without exceptions apply in countries like and , where is listed under national narcotic schedules with penalties up to 10 years imprisonment for possession.

Recent Decriminalization and Policy Shifts

In May 2019, Denver became the first U.S. city to decriminalize psilocybin mushrooms by voter initiative, directing law enforcement to make enforcement of personal use and possession the lowest priority. Subsequent municipal actions followed, including Oakland and Santa Cruz in California decriminalizing entheogenic plants including psilocybin in 2019, and over a dozen other cities such as Ann Arbor, Michigan (2020), and Washington, D.C. (2020) deprioritizing prosecution for possession and cultivation by 2021. These local measures typically reduced penalties without full legalization, reflecting a harm-reduction approach amid growing research on psilocybin's therapeutic potential for conditions like depression and PTSD. At the state level, Oregon's Measure 109, approved by voters in November 2020 with 56% support, established a regulated framework for supervised service centers, legalizing facilitated adult use while decriminalizing possession of up to 12 grams of dried mushrooms or 2.5 grams of as the lowest enforcement priority. Licensing for service centers began in January 2023, with operations expanding despite regulatory hurdles; by 2025, new administrative rules adjusted session protocols and center requirements to address implementation challenges, though access remains limited to adults 21 and older in licensed settings. followed in November 2022 via Proposition 122, decriminalizing personal use of natural psychedelics including and authorizing regulated therapeutic programs, with implementation advancing through state task forces by 2025. More recently, enacted legislation in 2025 establishing a for , building on prior penalty reductions for personal possession. Internationally, Australia marked a significant policy shift on July 1, 2023, when the Therapeutic Goods Administration reclassified psilocybin from a prohibited substance to a controlled medicine, permitting authorized psychiatrists to prescribe it for treatment-resistant depression under strict protocols, making Australia the first nation to approve its therapeutic use without full trial completion. This authorization requires individual patient approvals and confines access to clinical settings, with no over-the-counter availability; by 2025, implementation continued amid debates over efficacy evidence and access equity. In August 2024, Olympia's city council in Washington state decriminalized plant-based hallucinogens including psilocybin, aligning with broader U.S. trends toward local reform despite federal Schedule I classification under the Controlled Substances Act, which prohibits non-research use nationwide. Legislative proposals for further decriminalization or regulation proliferated in states like California and Texas in 2025, though federal barriers persist, with reform bills increasing from 27 in 2021 to 36 in 2022 and continuing upward.

References

  1. https://www.pnas.org/doi/10.1073/pnas.2311245121
  2. https://www.semanticscholar.org/paper/The-genus-Psilocybe-%253A-a-systematic-revision-of-the-Guzm%25C3%25A1n/8b94d2bec6f05bfa0248373389e213f2073eac1d
  3. https://www.nature.com/articles/s41586-024-07624-5
  4. https://www.researchgate.net/publication/254725842_Supplement_to_the_monograph_of_the_genus_Psilocybe
  5. https://www.sciencedirect.com/science/article/pii/S1878614622000095
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9650681/
  7. https://medicine.washu.edu/news/mushrooms-generate-psychedelic-experience-by-disrupting-brain-network/
  8. https://mathenylab.utk.edu/Site/Publications_files/Redhead_conserve_Psilocybe_Taxon.2007.pdf
  9. https://www.irmng.org/aphia.php?p=taxdetails&id=1306525
  10. https://www.gbif.org/ar/species/144094032
  11. https://www.frontiersin.org/journals/forests-and-global-change/articles/10.3389/ffgc.2022.813998/full
  12. https://www.allbookstores.com/The-genus-Psilocybe-systematic-revision/9783768254748
  13. https://www.biorxiv.org/content/10.1101/2022.12.13.520147v1.full-text
  14. https://cdnsciencepub.com/doi/10.1139/cjb-2013-0070
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10801892/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC4510267/
  17. https://www.mdpi.com/1422-0067/23/22/14068
  18. https://www.researchgate.net/publication/226231019_Molecular_phylogeny_of_Psilocybe_cyanescens_complex_in_Europe_with_reference_to_the_position_of_the_secotioid_Weraroa_novae-zelandiae
  19. https://www.biorxiv.org/content/10.1101/2024.12.03.626483v1.full
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC11856550/
  21. https://www.etymonline.com/word/psilocybin
  22. https://www.gbif.org/species/144094032
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC10238702/
  24. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/psilocybe
  25. https://www.sciencedirect.com/topics/immunology-and-microbiology/psilocybe
  26. https://mushroomexam.com/magic-mushroom-lookalikes.html
  27. https://www.facebook.com/PaulStamets/posts/entoloma-serrulata-mycena-amicta-and-hypholoma-dispersum-pictured-here-are-among/1275081333986798/
  28. https://pnwspore.com/how-to-identify-magic-mushrooms/
  29. https://mycologyst.art/identification/poisonous-and-deadly-mushrooms/commonly-misidentified-mushrooms/
  30. https://explore.beatymuseum.ubc.ca/mushroomsup/G_marginata.html
  31. https://doubleblindmag.com/liberty-cap-look-alikes/
  32. https://a-z-animals.com/blog/mushrooms-that-look-like-liberty-caps/
  33. https://doubleblindmag.com/how-to-identify-psilocybe-cubensis-look-alikes/
  34. http://www.museocivico.rovereto.tn.it/UploadDocs/104_art09-Guzman%2520&%2520C.pdf
  35. https://www.zobodat.at/pdf/Sydowia_61_0215-0242.pdf
  36. https://journals.asm.org/doi/10.1128/mra.00250-24
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC11736257/
  38. https://www.frontiersin.org/journals/fungal-biology/articles/10.3389/ffunb.2023.1295223/full
  39. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838765
  40. https://pubs.acs.org/doi/10.1021/acsomega.5c05606
  41. https://pubmed.ncbi.nlm.nih.gov/14578010/
  42. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/psilocin
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9667540/
  44. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16466
  45. https://www.nature.com/articles/s41467-024-46997-z
  46. https://pubmed.ncbi.nlm.nih.gov/28763571/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC11046786/
  48. https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1873-3468.15042
  49. https://www.nature.com/articles/s41467-025-58239-x
  50. https://onlinelibrary.wiley.com/doi/full/10.1002/anie.202512017
  51. https://www.researchgate.net/publication/15998153_Variation_of_psilocybin_and_psilocin_levels_with_repeated_flushes_harvests_of_mature_sporocarps_of_Psilocybe_cubensis_Earle_Singer
  52. https://www.nature.com/articles/s41598-025-97710-z
  53. https://academic.oup.com/jaoac/advance-article/doi/10.1093/jaoacint/qsaf007/8019671
  54. https://journals.asm.org/doi/10.1128/aem.01498-22
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC12299699/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC9247433/
  57. https://www.sciencedirect.com/science/article/abs/pii/S1570963923000286
  58. https://pubmed.ncbi.nlm.nih.gov/30685771/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6785028/
  60. https://www.cambridge.org/core/journals/cns-spectrums/article/psilocybin-in-neuropsychiatry-a-review-of-its-pharmacology-safety-and-efficacy/AA1FB4F49C14BA3F398238D6E5A3947A
  61. https://www.nature.com/articles/s41593-023-01316-5
  62. https://www.nature.com/articles/s41467-025-62980-8
  63. https://www.cell.com/iscience/fulltext/S2589-0042%2824%2900908-8
  64. https://pubmed.ncbi.nlm.nih.gov/14615876/
  65. https://www.nature.com/articles/s41386-022-01297-2
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10661823/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC11007582/
  68. https://nida.nih.gov/research-topics/psilocybin-magic-mushrooms
  69. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00974/full
  70. https://pubmed.ncbi.nlm.nih.gov/34228959/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9665925/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC5870365/
  73. https://www.sciencedirect.com/science/article/abs/pii/S0924933805000933
  74. https://link.springer.com/article/10.1007/s00213-022-06066-z
  75. https://pubmed.ncbi.nlm.nih.gov/25637267/
  76. https://pubmed.ncbi.nlm.nih.gov/32194129/
  77. https://www.sciencedirect.com/science/article/abs/pii/S0149763419310413
  78. https://www.sciencedirect.com/science/article/abs/pii/S0924977X13003519
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC5603818/
  80. https://www.bps.org.uk/psychologist/looking-back-brief-history-psychedelic-psychiatry
  81. https://www.sciencedirect.com/science/article/pii/S002839081730638X
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC381240/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC5826346/
  84. https://medicine.yale.edu/psychiatry/research/clinics-and-programs/psychedelic/
  85. https://compasspathways.com/our-work/treatment-resistant-depression/
  86. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827553
  87. https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
  88. https://www.statnews.com/2025/06/23/compass-pathways-psilocybin-depression-treatment-meets-trial-goal/
  89. https://www.medscape.com/viewarticle/psilocybin-safe-effective-treatment-resistant-depression-2025a1000grn
  90. https://www.hcplive.com/view/compass-pathways-comp360-psilocybin-shows-benefit-in-phase-3-trd-trial
  91. https://clinicaltrials.ucsf.edu/psilocybin
  92. https://clinicaltrials.ucsd.edu/psilocybin
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC12491823/
  94. https://med.uth.edu/psychiatry/2024/06/03/fda-grants-breakthrough-therapy-designation-to-cyb003-a-deuterated-psilocybin-analog-being-investigated-as-an-adjunctive-treatment-for-major-depressive-disorder-mdd/
  95. https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC10350724/
  97. https://link.springer.com/article/10.1007/s00213-022-06221-6
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC10521293/
  99. https://www.sciencedirect.com/science/article/abs/pii/S0732118X2200037X
  100. https://www.sciencedirect.com/science/article/pii/S2666634022005190
  101. https://www.theguardian.com/science/2023/aug/19/therapeutic-potential-hallucinogens-risky-overhyped-lsd-mdma-psilocybin-work
  102. https://www.nature.com/articles/s41386-023-01656-7
  103. https://www.nejm.org/doi/full/10.1056/NEJMoa2032994
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC9963058/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC12001667/
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC9353971/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC6791528/
  108. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2817352
  109. https://www.sciencedirect.com/science/article/pii/S0278584624002458
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC1071149/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC8905125/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC9202314/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC10944581/
  114. https://calpoison.org/about-magic-mushrooms-psilocybin-safety
  115. https://pubmed.ncbi.nlm.nih.gov/39420616/
  116. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.22010073
  117. https://pubmed.ncbi.nlm.nih.gov/15963699/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC11869617/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC9834328/
  120. https://www.woodlandrecovery.com/blog/long-term-effects-shrooms/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC11835720/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC9120359/
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC11494431/
  124. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06303-z
  125. https://www.sciencedirect.com/science/article/pii/S2773021224000397
  126. https://www.nature.com/articles/s41598-023-41145-x
  127. https://pubmed.ncbi.nlm.nih.gov/39354706/
  128. https://pubs.acs.org/doi/10.1021/acsptsci.5c00202
  129. https://www.tandfonline.com/doi/full/10.1080/14740338.2023.2248883
  130. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Psilocybin%2520evidence%2520report%2520to%2520OHA%25206-30-21_Submitted.pdf
  131. https://www.sciencedirect.com/science/article/pii/S2173580814001527
  132. https://cswr.hds.harvard.edu/news/2024/10/ritual-and-religious-uses-psilocybe-mushrooms-mesoamerica
  133. https://pubmed.ncbi.nlm.nih.gov/32398764/
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC12125594/
  135. https://chacruna.net/mazatec-shamanism-and-psilocybin-mushrooms/
  136. https://akjournals.com/view/journals/2054/8/1/article-p3.xml
  137. https://jied.lse.ac.uk/articles/10.31389/jied.101
  138. https://www.chelseagreen.com/2021/the-magic-mushroom-a-history/
  139. https://www.acs.org/molecule-of-the-week/archive/p/psilocin.html
  140. https://psychology.fas.harvard.edu/people/timothy-leary
  141. https://www.sciencedirect.com/science/article/abs/pii/S0955395909001121
  142. https://www.rand.org/news/press/2024/06/27.html
  143. https://www.cnn.com/2025/04/21/health/psilocybin-use-poison-calls-wellness
  144. https://bioengineer.org/study-finds-rising-psilocybin-use-among-americans-particularly-those-with-mental-health-conditions/
  145. https://nida.nih.gov/news-events/news-releases/2024/02/law-enforcement-seizures-of-psilocybin-mushrooms-rose-dramatically-between-2017-2022
  146. https://www.hopkinsmedicine.org/news/articles/2024/05/survey-illuminates-effects-of-real-world-psilocybin-use
  147. https://www.npr.org/sections/shots-health-news/2024/06/27/nx-s1-5021788/magic-mushrooms-psilocybin-microdosing-psychedelics-trends
  148. https://pubmed.ncbi.nlm.nih.gov/39503411/
  149. https://microdosinginstitute.com/research-publications/global-trends-microdosing-demographics-substance-testing-behavior-patterns/
  150. https://theconversation.com/psychedelic-drugs-how-the-brains-of-informed-users-are-different-156244
  151. https://akjournals.com/view/journals/2054/8/1/article-p106.xml
  152. https://chacruna.net/set-setting-shape-psychedelic-cultures/
  153. https://www.unodc.org/pdf/convention_1971_en.pdf
  154. https://www.unodc.org/unodc/en/treaties/psychotropics.html
  155. https://transformdrugs.org/blog/can-we-legalise-psychedelics-under-the-un-drug-treaties
  156. https://archive.org/details/commentary_on_the_convention_1971
  157. https://psyclehealth.com/psychedelics/where-is-psilocybin-legal/
  158. https://psychedelicalpha.com/data/worldwide-psychedelic-laws
  159. https://psychedelics.berkeley.edu/law/
  160. https://www.bbc.com/future/article/20240320-legal-status-of-psychedelics-around-the-world
  161. https://worldpopulationreview.com/country-rankings/lsd-legal-countries
  162. https://recovered.org/hallucinogens/psilocybin/psilocybin-legal-status
  163. https://blog.mayya.com/exploring-magic-mushrooms-in-europe-legal-status-popularity-and-cultural-trends/
  164. https://psychedelicalpha.com/data/psychedelic-laws
  165. https://www.cato.org/regulation/summer-2025/future-psychedelic-regulation-local
  166. https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
  167. https://www.kdrv.com/news/top-stories/2025-is-bringing-changes-to-psilocybin-therapy-in-oregon-proponents-say-it-s-still-stigmatized/article_a4b33cfc-d2d7-11ef-9fdf-3b351cec10fa.html
  168. https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-administrative-rules.aspx
  169. https://reason.org/commentary/state-psychedelics-legalization-and-policy-roundup-june-2025/
  170. https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
  171. https://www.bbc.com/news/world-australia-66072427
  172. https://pubmed.ncbi.nlm.nih.gov/39701143/
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC10069558/
Add your contribution
Related Hubs
User Avatar
No comments yet.